Does genetic and pharmacologic inactivation of ANGPTL3 reduce lipid levels and atherosclerotic cardiovascular disease?
Genetic and pharmacologic inactivation of ANGPTL3 is associated with lowered major lipid fractions and reduced risk of atherosclerotic cardiovascular disease.
Genetic and therapeutic antagonism of ANGPTL3 in humans and of Angptl3 in mice was associated with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovascular disease. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT01749878 .).
Dewey et al. (Wed,) studied this question.